Evidence map›Paper›PMID 36644669›Full record

ArticleAtherosclerosis plus2021

Cholesterol efflux promoting function of high-density lipoproteins in calcific aortic valve stenosis.

Duygu Kocyigit, Francesca Zimetti, Kadri M Gurses, Ilaria Zanotti, Cinzia Marchi, Marcus Ståhlman, Jan Borén, Hande Canpinar, Mehmet F T Soyal, Dicle Guc and 3 more

Open access · goldAbstract read
In one paragraph

Article in Atherosclerosis plus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Duygu KocyigitDepartment of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Francesca ZimettiDepartment of Food and Drug, University of Parma, Parma, Italy.
Kadri M GursesDepartment of Basic Medical Sciences, Adnan Menderes University Faculty of Medicine, Aydin, Turkey.
Ilaria ZanottiDepartment of Food and Drug, University of Parma, Parma, Italy.
Cinzia MarchiDepartment of Food and Drug, University of Parma, Parma, Italy.
Marcus StåhlmanDepartment of Molecular and Clinical Medicine, University of Gothenburg Institute of Medicine, Göteborg, Sweden.
Jan BorénDepartment of Molecular and Clinical Medicine, University of Gothenburg Institute of Medicine, Göteborg, Sweden.
Hande CanpinarDepartment of Basic Oncology, Hacettepe University Institute of Oncology, Ankara, Turkey.
Mehmet F T SoyalDepartment of Cardiovascular Surgery, Medicana International Ankara Hospital, Ankara, Turkey.
Dicle GucDepartment of Basic Oncology, Hacettepe University Institute of Oncology, Ankara, Turkey.
Tuncay HazirolanDepartment of Radiology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Necla OzerDepartment of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Lale TokgozogluDepartment of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Hacettepe University · TRUniversity of Parma · ITHacettepe University Hospital · TRUniversity of Gothenburg · SEAdnan Menderes University · TRMemorial Ankara Hospital · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aims: Cholesterol efflux capacity is a functional property of high-density lipoproteins (HDL) reflecting the efficiency of the atheroprotective reverse cholesterol transport process in humans. Its relationship with calcific aortic valve stenosis (CAVS) has not been fully assessed yet. Methods: We evaluated HDL-CEC in a patient population with varying degrees of aortic valvular calcific disease, assessed using echocardiography and cardiac computed tomography. Measurement of biomarkers that reflect osteogenic and tissue remodeling, along with dietary and gut microbiota-derived metabolites were performed. Results: Patients with moderate-severe CAVS had significantly lower HDL-CEC compared to both control and aortic sclerosis subjects (mean: 6.09%, 7.32% and 7.26%, respectively). HDL-CEC displayed negative correlations with peak aortic jet velocity and aortic valve calcium score, indexes of CAVS severity (ρ = -0.298, p = 0.002 and ρ = -0.358, p = 0.005, respectively). In multivariable regression model, HDL-CEC had independent association with aortic valve calcium score (B: -0.053, SE: 0.014, p < 0.001), GFR (B: -0.034, SE: 0.012, p = 0.007), as well as with levels of total cholesterol (B: 0.018, SE: 0.005, p = 0.002). Conclusion: These results indicate an impairment of HDL-CEC in moderate-severe CAVS and may contribute to identify potential novel targets for CAVS management.

Indexed as

Aortic stenosisAortic valve calcium scoreCholineLipidsMatrix metalloproteinase

Identifiers

PMID36644669
PMCPMC9833266
OpenAlexW3195824494

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.